

3-29-02

09/922,584 \$208.00

M.E

- 1 -

VPI00-115 CIP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Kuida et al.,  
Serial No.: 09/922,584  
Filing Date: August 3, 2001  
For: ERK-5 DEFICIENT ANIMALS AND METHODS  
OF INHIBITING ANGIOGENESIS THROUGH  
THE INHIBITION OF ERK-5

Cambridge, Massachusetts  
March 28, 2002

Honorable Commissioner  
For Patents  
Washington, D.C. 20231

Attention: Application Processing Division,  
Special Processing and Correspondence  
Branch

TRANSMITTAL LETTER FOR EXECUTED DECLARATION AND SEQUENCE  
LISTING AND DISKETTE

Sir:

Transmitted herewith in response to the Notice  
Of Incomplete Nonprovisional Application - Filing Date  
Granted, mailed January 3, 2002, are the following  
materials relating to the above-identified application:


1. Statement under 37 C.F.R. 1.82.1  
Certification of Sequence Listing

2. Diskette containing Sequence Listing and paper copy of sequence list
3. Executed Declaration and Power of Attorney
4. Copy of Notice Of Incomplete Nonprovisional Application - Filing Date Granted
5. Petition for Extension of Time (2 Months)

Applicants hereby authorize the Commissioner to charge Deposit Account No. 50-0725 in the amount of \$166.00 Rule 37 C.F.R. 1.26(a) (\$130.00 late filing of Oath and Declaration and \$36.00 for 13 additional claims over 20).

Applicant's believe that no additional fees are due at this time however, the Commissioner is hereby authorized to charge payment of additional fees required under 37 C.F.R. 1.16 in connection with the paper transmitted herewith, or credit any overpayment of same, to Deposit Account No. 50-0725. A duplicate copy of this transmittal letter is transmitted herewith.

Respectfully submitted,

  
Andrea L.C. Robidoux (Reg. No. 47,902)  
Agent for Applicants  
Vertex Pharmaceuticals Inc.  
130 Waverly Street  
Cambridge, MA 02139-4242  
Tel.: (617) 444-6731  
Fax.: (617) 444-6483



UNITED STATES PATENT AND TRADEMARK OFFICE

Page 1 of 2 #6  
COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/922,584	08/03/2001	Keisuke Kuida	VPI/00-115 CIP

CONFIRMATION NO. 9797

FORMALITIES LETTER



\*OC000000007263647\*

Andrea L. C. Robidoux  
Vertex Pharmaceuticals Incorporated  
130 Waverly Street  
Cambridge, MA 02139-4242

Date Mailed: 01/03/2002

NOTICE OF INCOMPLETE REPLY (NONPROVISIONAL)

*Filing Date Granted*

The U.S. Patent and Trademark Office has received your reply on 12/03/2001 to the Notice to File Missing Parts (Notice) mailed 10/03/2001 and it has been entered into the nonprovisional application. The reply, however, does not include the following items required in the Notice.

The period of reply remains as set forth in the Notice. You may, however, obtain EXTENSIONS OF TIME under the provisions of 37 CFR 1.136 (a) accompanied by the appropriate fee (37 CFR 1.17(a)).

A complete reply must be timely filed to prevent ABANDONMENT of the above-identified application.

The required items noted below SHOULD be filed along with any items required above. The filing date of this nonprovisional application will be the date of receipt of the items required above.

- Total additional claim fee(s) for this application is \$36.
  - \$36 for 13 total claims over 20.
- The oath or declaration is missing.  
*A properly signed oath or declaration in compliance with 37 CFR 1.63, identifying the application by the above Application Number and Filing Date, is required.*
- Late filing fee or oath or declaration surcharge as set forth in 37 CFR 1.16(e) of \$130 was not received.
- The balance due by applicant is \$ 166.
- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216

04/03/2002 CCHAU1 00000077 500725 09922584

01 FC:105  
02 FC:103

130.00 CH  
36.00 CH

- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

---

*A copy of this notice **MUST** be returned with the reply.*



Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE